Left Ventricular Systolic Dysfunction clinical trials at UCLA
1 research study open to eligible people
Showing trials for
Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
open to eligible people ages up to 17 years
This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.
Los Angeles, California and other locations
Our lead scientists for Left Ventricular Systolic Dysfunction research studies include Nancy J. Halnon, MD.
Last updated: